1)Sugaya N, et al:Very low pandemic influenza A(H1N1)2009 mortality associated with early neuraminidase inhibitor treatment in Japan:Analysis of 1000 hospitalized children. J Infect 63:288-294, 2011
2)Yao D, et al:Thermal instability of compound variants of carnitine palmitoyltransferase Ⅱ and impaired mitochondrial fuel utilization in influenza-associated encephalopathy. Hum Mutat 29:718-727, 2008
3)Heinonen S, et al:Early oseltamivir treatment of influenza in children 1-3 years of age:a randomized controlled trial. Clin Infect Dis 51:887-894, 2010
4)Sugaya N, et al:Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56:369-377, 2012
5)Sugaya N, et al:Long-acting neuraminidase inhibitor laninamivir octanoate(CS-8958)versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 54:2575-258, 2010
6)Takashita E, et al:A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014;19(1). pii:20666
7)Sugaya N, et al:Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Antivir Ther 2014(in press)
8)Reichert TA, et al:The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344:889-896, 2001
9)Charu V, et al:Influenza-related mortality trends in Japanese and american seniors:evidence for the indirect mortality benefits of vaccinating schoolchildren. PloS one. 2011;6(11):e26282.
10)Sugaya N, et al:Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan. Clin Infect Dis 41:939-47, 2005
11)Kawai S, et al:Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin Infec Dis 53:130-136, 2011
12)Skowronski DM, et al:Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PloS one. 2014;9(3):e92153